Companies Cryptocurrencies
Editas Medicine Inc
Editas Medicine Inc
Exchange: Nasdaq Global Select
IPO Date: 03/02/2016
CEO: Ms. Cynthia Collins
Biotechnology Healthcare 🔗
  • EDIT
  • 53.09
  • 3623992320
    market cap
  • -4.75
If you bought

shares of Editas Medicine Inc (EDIT) on
You would have made
Old Price $12 Current Price $12

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 133 full-time employees. The company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The company operates through developing and commercializing genome editing technology segment. The company is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. The company is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Address: 11 Hurley St Cambridge MASSACHUSETTS 02141

Stay updated.